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bjectives Our aim was to study the relationships between total stent length (TSL) and long-term
linical outcomes after sirolimus-eluting stent (SES) implantation.
ackground SES compared with bare-metal stent use for long lesion treatment is associated with
educed restenosis rates.
ethods Three-year follow-up data were available for 10,773 patients (14,651 lesions) that had
een treated with only SES (Cypher, Cordis Corp., Warren, New Jersey) in the j-Cypher registry. Pa-
ients and lesions were divided into quartile groups: TSL per patient (Q1: 8 to 23 mm, Q2: 24 to 36
m, Q3: 37 to 54 mm, Q4: 55 to 293 mm), and TSL per lesion (QA: 8 to 18 mm, QB: 19 to 23 mm,
C: 24 to 33 mm, QD: 34 to 150 mm).
esults In per-lesion data, longer TSL increased target lesion revascularization (TLR) rates but did
ot increase stent thrombosis rates (p  0.2324). In per-patient data, the incidences of TLR remark-
bly increased with increasing TSL. Incidence of composite of death and myocardial infarction also
ncreased with increasing TSL; however, after adjustment for baseline differences, there was no sta-
istical signiﬁcance. Deﬁnite stent thrombosis rate in group Q4 was signiﬁcantly higher than in other
roups, both unadjusted (hazard ratio: 1.770, p  0.0081) and adjusted (hazard ratio: 1.727, p 
.0122) for baseline differences.
onclusions TSL per lesion and patient had signiﬁcantly impacts on TLR rates. Longer TSL per
atient was associated with increased incidence of stent thrombosis through 3 years. (J Am Coll
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181ultiple and long bare-metal stent (BMS) implantation
s associated with a greater incidence of restenosis (1–3),
ith diffuse in-stent restenosis (ISR) being the most
ommon pattern. Diffuse ISR is, in turn, the major risk
actor for malignant recurrent ISR, and, therefore, long-
egment BMS implantation is associated with a poor
linical outcome (4,5). Randomized clinical trials and
egistries including complex coronary lesions have shown
hat sirolimus-eluting stents (SES) (Cypher, Cordis Corp.,
See page 189
arren, New Jersey) reduce the need for revascularization
herapy and provide clinical efficacy in routine practice, as
ompared with BMS (6–13). This remains true even in the
ontext of the current trend to use a drug-eluting stent
DES) for full coverage of atherosclerotic lesions (i.e.,
tented segment length tends to be longer than the lesion
ength) (6). SES implantation for long lesions with multiple
tents is efficacious for reduction of restenosis (14–17);
owever, long-term safety remains a concern, particularly
ith regard to late and very late thrombosis (18–21).
The relationships between total stent length (TSL) for
ES and rates of late adverse events, including target
esion revascularization (TLR) and stent thrombosis
ST), have not been examined. Therefore, the objective
f this study was to determine the 3-year cumulative
ncidences of clinical events including death, myocardial
nfarction, stroke, TLR, and ST according to TSL per
esion and per patient using data derived from the
-Cypher registry.
ethods
tudy population. The design and 2-year outcome of the
-Cypher registry has been published previously (22). In
rief, the j-Cypher registry is a physician-directed multi-
enter registry of consecutive patients undergoing SES
mplantation at 37 centers in Japan. The study protocol was
pproved by the relevant review boards or ethics committees
n the participating centers (22). Written informed consent
or enrollment in the registry was obtained from all patients.
Consecutive patients undergoing percutaneous coronary
ntervention (PCI) were registered in the PCI log form by
echnical staff at each center, and more than 50% of the case
eport forms were audited by the clinical research coordi-
ators (22) in the data management center. Entry of
etailed baseline and follow-up data for patients undergoing
t least 1 SES implantation was performed via the Internet.
ollow-up data were obtained from hospital charts or by
ontacting patients or referring physicians at 30 days, 6
onths, and 1 year after the procedure, and yearly thereaf-
er. Upon reports of important clinical events such as death,
yocardial infarction, and ST, original source documents dere requested to be sent to the data center, and the events
ere evaluated by the clinical events committee (22).
Between August 2004 and November 2006, a total of
5,155 patients were enrolled in the registry from 29,555
onsecutive patients undergoing PCI. SES implantation rates
aried markedly among centers, with a median rate of 53% and
range of 16% to 92%. After exclusion of 2,331 patients who
ere registered more than once due to PCI for restenosis or
ew lesions, 12,824 patients were newly enrolled in the
egistry. Among 19,675 target lesions, 17,050 were treated
xclusively with SES. Treatment for the remaining 2,625
esions included BMS (1,259 lesions), a combination of SES
nd other stent types (495 lesions), other DES (60 lesions),
onstent PCI (672 lesions), failed procedures (139 lesions),
nd data not available (10 lesions). Finally, 10,773 patients who
ere exclusively treated with SES
ere identified as the population
or the current analysis.
In this subanalysis of the
-Cypher registry, the patients
nd lesions were each grouped
ased on quartiles. For per-
atient data for TSL, the lower,
edian, and upper borders of
uartiles of TSL were 23, 36,
nd 54 mm, respectively, and for
er-lesion data these borders
ere 18, 23, and 33 mm, respec-
ively. Based on these data, there
ere 4 total stent length groups
ach per patient (TSL-P) and
er lesion (TSL-L), respectively
Fig. 1).
esion and patient evaluation.
oronary angiographic parame-
ers including reference vessel
iameter, percentage stenosis di-
meter, and lesion length were
ssessed in each participating
enter by either visual assessment or quantitative angiogra-
hy. A lesion was defined as the area covered by a single
tent or multiple overlapping stents. When 2 stents were
laced without overlap, the 2 treated areas were regarded as
separate lesions. When multiple overlapping stents were
laced from the left main coronary artery to the left anterior
escending coronary artery, these areas were also regarded as
separate lesions, despite placement of overlapping stents.
esions located within 3 mm from the ostium were re-
arded as ostial lesions.
Death was regarded as cardiac in origin unless an obvious
oncardiac cause could be identified. Myocardial infarction
as adjudicated according to the definition in the ARTS
Arterial Revascularization Therapy Study) (23). TLR was
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass graft
CI  confidence interval
DES  drug-eluting stent(s)
HR  hazard ratio
ISR  in-stent restenosis
PCI  percutaneous
coronary intervention
RR  relative risk
SES  sirolimus-eluting
stent(s)
ST  stent thrombosis
TLR  target lesion
revascularization
TSL  total stent length
TSL-L  total stent length
group per lesion
TSL-P  total stent length
group per patientefined as either PCI or coronary artery bypass graft
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182CABG) surgery due to restenosis or thrombosis of the
arget lesion, including proximal and distal edge segments.
T was defined according to the Academic Research Con-
ortium definition (24). Academic Research Consortium
efinite ST was used as the end point for ST in this study
22). The recommended antiplatelet regimen consisted of
spirin (81 mg daily) indefinitely and thienopyridine (200
g ticlopidine or 75 mg clopidogrel daily) for at least 3
onths. The duration of dual antiplatelet therapy was left to
he discretion of each attending physician. In this study,
umulative 3-year rates of TLR were evaluated based on the
SL-P and TSL-L groupings; the cumulative 3-year inci-
ence of definite ST was also evaluated in the same groups,
hile the cumulative 3-year incidence of death/myocardial
nfarction was evaluated in the TSL-P groups (i.e., at the
atient level only because the definitions included events
nrelated to the lesions per se).
tatistical analysis. Discrete variables are reported as num-
ers and percentages and continuous variables as means 
D. Categorical variables were compared with the chi-
quare test, while continuous variables were compared using
he Student t test. Clinical event rates at 1, 2, and 3 years
ere compared by chi-square test. Cumulative incidences
ere estimated by the Kaplan-Meier method, and differ-
nces were assessed with the log-rank test.
The longest TSL-P group was considered as a risk factor
or clinical outcomes, and the other 3 groups were combined
Figure 1. Classification of Patients and Lesions Into 4 Groups According to
Total stent length per patient (A) and per lesion (B) was divided into 4 group
quartile and upper borders of quartile were 23 and 54 mm (Q1: 8 to 23 mm [n
293 mm [n  2,184]), respectively. Median of total stent length per lesion was
mm [n  5,361], QB: 19 to 23 mm [n  3,515], QC: 24 to 33 mm [n  2,401],s 1 comparison group. We used the Cox proportional tazard model to estimate hazard ratios (HRs) and their 95%
onfidence intervals (CIs) for the longest TSL-P group
ompared with the comparison group. Because the length of
he stent was significantly associated with conditions of
atients, we developed a propensity score for the longest
SL-P using logistic regression model, with the longest
SL-P as a response variable and the 16 variables (age, sex,
ody mass index, ST-segment elevation myocardial infarc-
ion, acute coronary syndrome, heart failure, prior PCI,
rior CABG, prior myocardial infarction, prior stroke,
eripheral artery disease, hemodialysis, estimated glomeru-
ar filtration rate 30 ml/min without hemodialysis, hyper-
ension, current smoking, diabetes mellitus with insulin
herapy) as explanatory variables. We developed Cox pro-
ortional hazard models to estimate the adjusted HRs for
linical events with variables of the longest TSL-P, propen-
ity score, and the 16 variables mentioned in the preceding
ext. We used SAS version 9.1 (SAS Institute Inc, Cary,
orth Carolina). Values of p  0.05 were considered
tatistically significant.
esults
atient characteristics. Patient characteristics are shown in
able 1, top. Age, sex, or proportions of individuals with
cute coronary syndrome at presentation, ST-segment
levation myocardial infarction, prior myocardial infarc-
tile
rding to quartile. Median of total stent length per patient was 36 mm. Lower
647], Q2: 24 to 36 mm [n  1,873], Q3: 37 to 54 mm [n  2,069], Q4: 55 to
m. Lower and upper borders of quartile were 18 and 33 mm (QA: 8 to 18
4 to 150 mm [n  3,374]), respectively.Quar
s acco
 4,
23 mion, and hemodialysis status did not differ significantly
a
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183mong the 4 groups. However, patients in group Q4 had
ignificantly higher incidences of diabetes (with or with-
ut insulin therapy), smoking habit, prior stroke, periph-
ral vascular disease, prior heart failure, poor left ventric-
lar function (ejection fraction 40%), and multivessel
isease compared with those in the other 3 groups. The
Table 1. Baseline Characteristics
Patient Characteristics Q1 Q
Number of patients 4,647 1,8
Age (yrs) 68.3 10.2 68.8
Age 80 yrs 580 (12.5%) 228 (
Women 1,179 (25.3%) 452 (
Body mass index (kg/m2) 23.9 3.3 24.0
Hypertension 3,421 (73.6%) 1,401 (
Diabetes 1,739 (37.4%) 723 (
On insulin 353 (7.6%) 158 (
Current smoking 902 (19.4%) 344 (
eGFR 30 ml/min/1.73 m2
Without hemodialysis 19 (4.3%) 92 (
With hemodialysis 250 (5.4%) 100 (
ACS 975 (21.0%) 404 (
STEMI 305 (6.6%) 145 (
Prior myocardial infarction 1,259 (27.1%) 545 (
Prior stroke 384 (8.3%) 173 (
Peripheral vascular disease 508 (11.0%) 228 (
Prior heart failure 541 (11.6%) 246 (
Prior PCI 2,341 (50.4%) 914 (
Prior CABG 337 (7.3%) 130 (
Multivessel disease 1,647 (35.4%) 847 (
Ejection fraction (%) 59.3 12.8 58.3
Ejection fraction 40% (%) 9.1
Total stent length (mm) 19.6 3.0 31.8
Thienopyridine use 1 yr (%) 62.7
Lesion Characteristics QA Q
Number of lesions 5,361 3,
Lesion location
LAD 2,040 (38.15%) 1,498
LCX 1,427 (26.6%) 743
RCA 1,613 (30.0%) 1,140
LMCA 208 (3.9%) 110
Saphenous vein graft 58 (1.08%) 22
In-stent restenosis 535 (10.0%) 461
Chronic total occlusion 125 (2.3%) 200
Severe calciﬁcation 344 (6.4%) 263
Bifurcation 830 (15.5%) 667
Reference diameter pre 2.5 mm 1,508 (28.1%) 982
Post-dilation (%) 2,026 (37.8%) 1,430
Total stent length (mm) 17.4 1.6 23.0
Minimal stent size (mm) 2.94 0.39 3.00
Continuous variables were expressed as mean value SD.
ACS acute coronary syndrome; CABG coronary artery bypass grafting; eGFR estimated
LMCA  left main coronary artery; PCI  percutaneous coronary intervention; RCA  right corumber of treated lesions increased according to TSL per Matient. The proportion of patients with thienopyridine
se 1 year increased with increasing TSL per patient.
esion characteristics. Lesion characteristics are listed in
able 1, bottom. Proportions of adverse lesion morphol-
gies, such as total occlusion and ostial or severely
alcified lesions, increased according to TSL per lesion.
Q3 Q4 p Value
2,069 2,184
68.4 10.0 68.1 10.6 0.1676
254 (12.3%) 299 (13.7%) 0.4062
491 (23.7%) 530 (24.2%) 0.4436
24.0 3.3 24.0 3.5 0.2861
1,589 (76.8%) 1,653 (75.6%) 0.0328
922 (44.6%) 1,014 (46.4%) 0.0001
226 (10.9%) 259 (11.9%) 0.0001
387 (18.7%) 485 (22.2%) 0.0001
104 (5.3%) 136 (6.6%) 0.0016
116 (5.6%) 127 (5.8%) 0.8770
445 (21.5%) 484 (22.25%) 0.7343
139 (6.7%) 136 (6.3%) 0.2468
614 (29.7%) 606 (27.7%) 0.1149
203 (9.8%) 247 (11.3%) 0.0007
237 (11.5%) 303 (13.9%) 0.0051
295 (14.3%) 378 (17.3%) 0.0001
1,021 (49.3%) 899 (41.2%) 0.0001
150 (7.2%) 170 (7.8%) 0.7686
1,233 (59.8%) 1,663 (76.1) 0.0001
57.9 13.3 55.5 13.7 0.0001
10.9 14.9 0.0001
45.5 4.3 80.0 25.1 0.0001
65.4 72.1 0.0001
QC QD p Value
2,401 3,374
) 1,090 (45.4%) 1,466 (43.4%) 0.0001
) 428 (17.8%) 490 (14.5%) 0.0001
) 814 (33.9%) 1,274 (37.8%) 0.0001
50 (2.1%) 129 (3.8%) 0.0003
) 16 (0.67%) 13 (0.38%) 0.0018
) 335 (14.0%) 554 (16.4%) 0.0001
262 (10.9%) 672 (19.9%) 0.0001
208 (8.7%) 453 (13.4%) 0.0001
) 472 (19.7%) 883 (26.2%) 0.0001
) 753 (31.4%) 901 (26.7%) 0.002
) 1,261 (52.5%) 1,767 (52.5%) 0.0001
29.6 2.3 51.7 15.7 0.0001
2.86 0.24 2.76 0.33 0.0001
ular filtration rate; LAD left descending coronary artery; LCX left circumflex coronary artery;
rtery; STEMI  ST-segment elevation myocardial infarction.2
73
 9.9
12.2%)
24.1%)
 3.5
74.8%)
38.6%)
8.4%)
18.4%)
5.2%)
5.3%)
21.6%)
7.7%)
29.1%)
9.2%)
12.2%)
13.1%)
48.8%)
6.9%)
45.2%)
 13.9
11.3
 3.6
60.1
B
515
(42.6%
(21.1%
(32.4%
(3.1%)
(0.63%
(13.1%
(5.7%)
(7.5%)
(19.0%
(27.9%
(40.7%
 0.3
 0.41
glomerinimal stent size was smallest in group QD. In group
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184A, the left circumflex coronary artery was a more
requent site of stent implantation while the left descend-
ng coronary artery and right coronary artery were less
requent sites compared with the other groups.
umulative 3-year clinical outcomes. Cumulative incidences
f death, cardiac death, myocardial infarction, stroke, TLR,
nd definite ST are listed in Table 2.
umulative 3-year rates of TLR. The incidences of TLR
ates in lesion and patient level were remarkably increased
ccording to the TSL. The cumulative total 3-year TLR
ate for all lesions was 8.1% (1,189 lesions). The 3-year
LR rates for the TSL-P groups were 7.47% in Q1; 10.99%
n Q2 (hazard ratio [HR]: 1.53, 95% CI: 1.25 to 1.85, p 
.0001 vs. Q1); 14.40% in Q3 (HR: 2.05, 95% CI: 1.73 to
.43, p  0.0001 vs. Q1); and 21.18% in Q4 (HR: 3.19,
5% CI: 2.74 to 3.71, p  0.0001 vs. Q1) (Fig. 2A). The
-year TLR rates for the TSL-L groups were 6.78% in QA;
.08% in QB (HR: 1.24, 95% CI: 1.05 to 1.48, p 0.0135 vs.
A); 10.96% in QC (HR: 1.71, 95% CI: 1.43 to 2.05, p 
.0001 vs. QA); and 15.57% in QD (HR: 2.65, 95% CI: 2.28
o 3.07, p  0.0001 vs. QA) (Fig. 2B).
umulative 3-year rates of deﬁnite ST, and composite of
eath and myocardial infarction. The 3-year definite ST rates
Table 2. Cumulative Clinical Event Rates Through 3 Years
Q1 Q2 Q3 Q4 p Value
Death
At 1 yr 3.21% 4.27% 4.20% 3.94% 0.0845
At 2 yrs 5.23% 6.14% 6.72% 7.10% 0.0099
At 3 yrs 6.67% 7.42% 8.46% 8.56% 0.0125
Cardiac death
At 1 yr 1.72% 2.62% 2.32% 2.84% 0.0139
At 2 yrs 2.50% 3.42% 3.43% 3.98% 0.0058
At 3 yrs 2.97% 4.06% 3.96% 4.76% 0.0019
Myocardial infarction
At 1 yr 1.31% 1.28% 1.74% 2.43% 0.0041
At 2 yrs 1.61% 1.92% 2.37% 3.00% 0.0022
At 3 yrs 1.92% 2.72% 3.04% 3.71% 0.0001
Stroke
At 1 yr 1.46% 1.76% 1.69% 2.47% 0.0318
At 2 yrs 2.35% 2.67% 2.71% 3.62% 0.0281
At 3 yrs 3.03% 3.26% 3.00% 4.12% 0.0993
Target lesion
revascularization
At 1 yr 3.83% 5.93% 7.78% 12.23% 0.0001
At 2 yrs 5.25% 8.01% 10.92% 16.44% 0.0001
At 3 yrs 7.47% 10.99% 14.40% 21.18% 0.0001
Deﬁnite stent
thrombosis
At 1 yr 0.45% 0.48% 0.63% 0.73% 0.3057
At 2 yrs 0.58% 0.75% 0.87% 1.05% 0.1878vAt 3 yrs 0.69% 0.96% 0.97% 1.42% 0.0353n the TSL-L groups were 0.60% in QA; 0.54% in QB; 0.79%
n QC; and 0.89% in QD (Fig. 3A). There were no significant
ifferences in definite ST rates among the quartiles of TSL-L.
n contrast to the per-lesion data, the cumulative 3-year
efinite ST rates in the TSL-P groups were 0.69% in Q1;
.96% in Q2 (HR: 1.43, 95% CI: 0.81 to 2.55, p  0.2245
Figure 2. Cumulative TLR Rates Based on TSL-P and TSL-L
Estimated target lesion revascularization (TLR) rates based on (A) total
stent length per patient (TSL-P) and (B) total stent length per lesion (TSL-L)
up to 3 years before adjustment for baseline characteristics. The incidences
of TLR rates in both patient and lesion level were increasing remarkably
(log-rank p  0.0001 in TSL-P and TSL-L) according to total stent length
before adjustment for baseline characteristics.s. Q1); 0.97% in Q3 (HR: 1.41, 95% CI: 0.80 to 2.46,
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185 0.2307 vs. Q1); and 1.42% in Q4 (HR: 2.11, 95% CI: 1.29
o 3.47, p  0.0031 vs. Q1) (Fig. 3B). The ST rate in group
Figure 3. Three-Year Cumulative Incidences of Definite ST Based on
TSL-P and TSL-L
Estimated deﬁnite stent thrombosis (ST) rates based on (A) TSL-P and
(B) TSL-L up to 3 years before adjustment for baseline characteristics.
There were no signiﬁcant differences in deﬁnite ST rates in lesion level
data according to total stent length (B). However, the incidences of def-
inite ST in the longest total stent length group per patient, group Q4,
was signiﬁcantly higher than that in the shorter stent length group (A).
Abbreviations as in Figure 2.4 was significantly higher than that in group Q1.The incidence of composite of death and myocardial infarc-
ion also increased according to increases in TSL per patient
Fig. 4). HRs of clinical events before and after adjustment are
hown in Table 3. TLR and definite ST rate in Q4 remained
ignificantly higher than in other stent length groups; however,
eath and myocardial infarction rate in Q4 was not statistically
ignificant after adjustment for baseline characteristics.
iscussion
lthough the efficacy and safety of multiple DES implan-
ation for long coronary lesion treatment has been the
ubject of previous reports (15–17), the follow-up periods
Figure 4. Three-Year Cumulative Incidence of Death and MI in
the TSL-P Groups
Estimated composite of death and myocardial infarction (MI) rates in total
stent length per patient (TSL-P). Cumulative 3-year incidences of composite
of death and MI increased signiﬁcantly according to the increase in TSL-P
before adjustment for baseline characteristics.
Table 3. Unadjusted and Adjusted HRs for Clinical Events in Group Q4 as
Compared With Group Q1, Q2, and Q3
HR 95% CI p Value
Unadjusted HRs of clinical event rates
Target lesion revascularization 2.343 2.070–2.651 0.0001
Deﬁnite stent thrombosis 1.770 1.160–2.702 0.0081
Death/myocardial infarction 1.217 1.049–1.413 0.0096
Adjusted HRs of clinical event rates
Target lesion revascularization 2.355 2.079–2.668 0.0001
Deﬁnite stent thrombosis 1.727 1.126–2.646 0.0122
Death/myocardial infarction 1.057 0.909–1.230 0.4684CI confidence interval; HR hazard ratio.
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186ere usually limited to 6 to 12 months, and the sample sizes
ere generally small.
This is the first publication based on a large population
egistry (number of patients 10,000) with long-term (up
o 3 years) follow-up and outcome data analyzed across
ifferent stent lengths.
At 3-year follow up, increases in TSLs both per lesion
nd per patient were associated with incremental increase in
LR rates, while only TSL per patient was significantly
ssociated with ST in unadjusted and adjusted data analyses.
he incidences of composite of death and myocardial
nfarction also increased according to increased TSL per
atient, however, there were no significant differences in the
djusted risk of composite of death and myocardial infarc-
ion according to the TSL-P.
Long and multiple BMS stent implantation is associated
ith increased restenosis and ST rates (1–4), whereas SES
mplantation has been shown to reduce restenosis and the
eed for revascularization in several randomized clinical
rials and large registries (6–17). Consistent with previous
eports (25,26), long and multiple SES implantation is
ssociated with increased risks of restenosis and need for
evascularization in this study, regardless of evaluation based
n TSL per lesion or per patient. However, the frequency of
epeat revascularization was lower compared with BMS
mplantation (6–9), despite the potential damage to the
essel wall and the high metal density.
However, the 3-year TLR rates were as high as 21.2% in
roup Q4 (TSL per patient 56 to 293 mm) and 15.6% in group
D (TSL per lesion 34 to 150 mm). This result is consistent
ith the finding in the SYNTAX (Synergy Between Percuta-
eous Coronary Intervention With TAXUS and Cardiac
urgery) trial (27) that the rate of the major adverse cardiac
vents increased as the SYNTAX score increased. Therefore,
e should admit that the complex procedures with extensive
overage of the coronary artery with SES are associated with
ubstantial risk of repeated procedures. When these types of
omplex procedures are planned, the risk and the benefit
gainst CABG surgery should be seriously assessed. Also, the
ecently reported FAME (Fractional Flow Reserve Versus
ngiography for Multivessel Evaluation) trial result suggested
hat PCI guided by physiologic lesion assessment in patients
ith multivessel disease resulted in less lesions treated and
mproved clinical outcome (28). Our observation is in line with
his FAME trial result.
While inhibition of cellular proliferation results in re-
uced neointimal hyperplasia and lower restenosis rates with
ES, it may also delay endothelialization of the stent surface
nd increase the risk of ST. For instance, in the Bern and
otterdam study, ST was reported to occur at a continuous
ate of 0.4% to 0.6% per year for up to 4 years without
iminution (29). The mechanism underlying late throm-
otic events has not been fully elucidated, but several
ypotheses have been proposed, including impaired re- sndothelialization from angioscopic (30) or autopsy findings
31), hypersensitivity to polymers (32), and nonresponsive-
ess to thienopyridine and aspirin (33). Premature discon-
inuation of dual antiplatelet therapy has been associated
ith a higher incidence of ST, and this has led to the
ecommendation of therapy with aspirin and thienopyridine
or at least 12 months (34). However, in a recent observa-
ional study based on the j-Cypher registry, Kimura et al.
22) reported an annual incidence of definite ST of 0.2% in
apan, with no apparent clinical benefit of thienopyridine
eyond 6 months after SES implantation. In our analysis,
he incidence of definite ST was higher in the long stent
roup despite higher rates of thienopyridine use for more
han 1 year. Optimal duration of dual antiplatelet therapy in
atients undergoing PCI with extensive metal coverage is
et to be defined.
Previous data have demonstrated that stent length is a risk
actor for acute and late ST (35,36) and major adverse cardiac
vents, including a meta-analysis of 10 randomized studies that
et the criteria of 9 to 12 months follow-up and antiplatelet
herapy of only 2 to 3 months. Orlic et al. (37) reported that
tent length per lesion and per patient are powerful indicators
or major adverse cardiac events in treatment of multivessel
isease with SES implantation; however, this report also had a
hort follow-up period of 6 months. Data from the Spanish
egistry ESTROFA (Estudio ESpan˜ol sobre TROmbosis
e stents FArmacoactivo) (38) and the Israeli arm of the
-Cypher registry (39) also show that stent length is an
ndependent predictor of subacute and late ST for up to 3
ears. In the second of these 2 analyses, stent length was
sed to denote the stent length per lesion, but the results
iffer from ours since stent length per lesion was not
ssociated with a risk for ST. The long stent implanted
roup had several adverse risks affecting long-term clinical
vents; therefore, the incidences of death and myocardial
nfarction through 3 years were significantly increased ac-
ording to increase TSL-P.
The SYNTAX trial showed an ST rate of 3.3% after 1
ear (35). In this trial, the mean TSL was 86.1 mm with 4.6
tents used to cover 3.6 lesions/patient. The 3.3% ST rate at
year suggests that complex procedures with implantation
f longer and multiple stents to treat multivessel disease may
e associated with an increased risk for ST. Our data also
ocumented higher ST rates in patients (group Q4) with
he longest TSL, and ST rates increased with number of
tents. However, the definite ST rate of 1.42% at 3 years in
roup Q4 in our patients with mean stent length of 80.0
m is markedly lower than 3.3% rate at 1 year reported in
he SYNTAX trial. The different ST rates in these studies
ould be due to ethnic differences, but the details remain to
e determined.
tudy limitations. This study has several limitations. First, it
as performed as a nonrandomized, observational, andingle-arm study. The absence of the control group under-
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187oing CABG makes it difficult to make any recommenda-
ion on the selection of coronary revascularization strategy.
econd, in our current analysis, stent fracture, which is
bserved as an extension of stent length and causes
efractory restenosis, was not analyzed. Third, clinically
riven and angiographically driven TLR were not differ-
ntiated. Relatively high rates of follow-up angiography
ight exaggerate the differences in TLR rate across the
uartiles of TSL.
onclusions
verall, our results suggest that the use of long and multiple
ES to fully cover a lesion was associated with a high incidence
f TLR, but not associated with increased ST for up to 3 years.
owever, treatment of multiple lesions with extensive metal
overage of the coronary artery increased the risk of TLR and
T. Total stent length was not associated with an increasing
isk of death and myocardial infarction after adjustment of
aseline characteristics.
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